Info

Vesta has made significant progress in developing proprietary methods of isolating, characterizing and manufacturing human hepatocytes directly from liver tissue, and these hepatocytes have been accepted by the FDA for use in early stage clinical trials. The Company is also developing methods to expand and differentiate hepatic progenitor cells. Vesta's approach is to use its technical strengths, patented intellectual property and know how in all stages of cell-based therapy to perfect and develop technologies to produce hepatocytes for therapeutic use. This approach can be summarized as the following three goals:Vesta will continue to optimize methods of expanding mature liver cells. Vesta will leverage its emerging proprietary strengths in hepatocyte progenitor cell isolation to conduct optimization studies on the expansion, differentiation and storage of these progenitor cells. Compared to mature hepatocytes, these cells have more extensive proliferative capacity, potentially expanding the use of a single donor organ to treat many patients. Vesta will examine the immunogenicity of expanded cells - mature hepatocytes and hepatocyte progenitor cells. With success in early clinical trials of mature hepatocytes and/or hepatocyte progenitor cells, the Company will seek one or more partners to take the products through late stage clinical development and into commercialization.